Monday, 10 July 2017, 6:30pm CEST
We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017.
During the briefing, Roche will discuss new data for emicizumab (ACE910) in hemophilia A:
HAVEN1 - phase 3 study of emicizumab (ACE910) prophylaxis in persons with hemophilia A with inhibitors
HAVEN2 - phase 3 study of emicizumab (ACE910) in pediatric persons with hemophilia A with inhibitors
Hotel Berlin, Berlin
Lützowplatz 17
10785 Berlin
Germany
map
Monday, 10 July 2017 @ 6:30pm CEST
The briefing will be followed by a buffet reception.
An invitation with the detailed programme and registration form will follow shortly.
Best regards,
Karl Mahler
Head of Investor Relations
Sabine Borngräber
Investor Relations Officer
get the latest news and updates to your inbox.